Objects
Jensen, Cathy J., Stankovich, Jim, Field, Judith, Danoy, Patrick, Brown, Matthew A., The Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), Lechner-Scott, Jeanette, Moscato, Pablo, Scott, Rodney J., Rubio, Justin P,, Butzkueven, Helmut, Van der Walt, Anneke, Bahlo, Melanie, Taylor, Bruce V,, van der Mei, Ingrid A. F., Foote, Simon J., Kilpatrick, Trevor J,, Johnson, Laura J., Wilkins, Ella. Public Library of Science; 2010. Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients.
Merlo, Daniel, Stankovich, Jim, Darby, David, Butzkueven, Helmut, Van der Walt, Anneke, Bai, Claire, Kalincik, Tomas, Zhu, Chao, Gresle, Melissa, Lechner-Scott, Jeannette, Kilpatrick, Trevor, Barnett, Michael, Taylor, Bruce. Wolters Kluwer Health; 2021. Association between cognitive trajectories and disability progression in patients with relapsing-remitting multiple sclerosis.
Hughes, Jordana, Jokubaitis, Vilija, Lugaresi, Alessandra, Hupperts, Raymond, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Ramo-Tello, Cristina, Trojano, Maria, Slee, Mark, Shaygannejad, Vahid, Boz, Cavit, Lechner-Scott, Jeanette, Van Pesch, Vincent, Pucci, Eugenio, Solaro, Claudio, Verheul, Freek, Terzi, Murat, Granella, Franco, Spitaleri, Daniele, Alroughani, Raed, Jun, Jae-Kwan, Fambiatos, Adam, Van der Walt, Anneke, Butzkueven, Helmut, Kalincik, Tomas. American Medical Association (AMA); 2018. Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis.
Yeh, Wei Zhen, Gresle, Melissa, Sampangi, Sandeep, Campagna, Maria Pia, Stankovich, Jim, Van der Walt, Anneke, Jokubaitis, Vilija, Butzkueven, Helmut, Lea, Rodney, Taylor, Bruce, Lucas, Robyn M., Ponsonby, Anne-Louise, Mason, Deborah, Andrew, Julie, Campbell, Hamish, Morahan, Julia. Academic Press; 2024. The immune cell transcriptome is modulated by vitamin D3 supplementation in people with a first demyelinating event participating in a randomized placebo-controlled trial.